Casgevy (exagamglogene autotemcel) for a Saudi family: what the pathway looks like in 2026

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

Sickle cell disease and transfusion-dependent beta-thalassemia have long histories in Saudi families, particularly in the Eastern Province and the south of the kingdom. Many families have lived with these conditions across multiple generations, often across multiple affected siblings. Casgevy is the first CRISPR-edited cell therapy approved anywhere in medicine. For a Saudi family considering it in 2026, the conversation is different from the chronic-transfusion or hydroxyurea world that the family already knows.

This page is meant to be the first honest read you get on Casgevy in Saudi Arabia, written by the team that would coordinate around your child's case if you decided to go forward. We assume your treating haematologist has raised this with you, or you have raised it with them.

We will be specific about who Casgevy is approved for, where it can be administered for a Saudi-based family, what the workup decides, the cost in SAR and US dollars, how the SFDA pathway works, what insurance and Vision 2030 frameworks may or may not cover, and what life looks like in the year after treatment.

What Casgevy actually is, in plain terms

Casgevy is the first approved CRISPR/Cas9 gene-edited cell therapy in medicine. It is given as a one-time treatment, but the operational reality is closer to a bone marrow transplant than a one-hour infusion.

Your child's own hematopoietic stem cells are mobilised out of the bone marrow into the blood, harvested through apheresis sessions, shipped to Vertex's manufacturing facility, edited using CRISPR/Cas9 at the erythroid-specific enhancer region of the BCL11A gene, and returned. The edited cells, once reinfused after myeloablative conditioning, reactivate fetal haemoglobin production. For sickle cell disease, fetal haemoglobin reduces sickling. For transfusion-dependent beta-thalassemia, it removes the requirement for chronic transfusions.

The edit is permanent. It does not cross to germline cells. Your child's future children will not inherit the edit. The change is hereditary only at the haematopoietic stem cell line, in your child's own bone marrow.

What Casgevy is not is a treatment that can be given outpatient. The conditioning protocol is myeloablative. The patient is admitted for the conditioning week, the infusion, and four to six weeks of recovery during pancytopenia and engraftment. Outpatient follow-up is monthly for the first year.

Who is currently a candidate, and who is not

The FDA, EMA, MHRA, and several MENA regulators have approved Casgevy for patients aged 12 and older with either sickle cell disease accompanied by recurrent vaso-occlusive crises, or transfusion-dependent beta-thalassemia. Your child must have a confirmed diagnosis and severity meeting the indication.

For SCD specifically, the case for Casgevy is strongest in patients with documented recurrent vaso-occlusive crises severe enough to interfere meaningfully with life. Most international centres look for that VOC history before proceeding.

For TDT, the case rests on a sustained regular transfusion requirement. Iron-overload assessment in patients who have been transfused for years is a routine part of the work-up.

If your child is under 12, Vertex is preparing 2026 submissions to expand the approved age range, but the current indication does not extend below age 12. We will not pretend otherwise. Reach out anyway. We can discuss what monitoring and supportive care fit between now and a potential future eligibility window.

If your child has SCD without documented VOC history, the case is harder. We will be honest about how international and Saudi tertiary centres will view that file.

The SFDA pathway in 2026

The Saudi Food and Drug Authority published its Gene Therapy Products Registration Guidelines in 2023, which standardised the registration and evaluation framework for advanced therapy medicinal products. This framework governs how cell and gene therapies are approved and imported into the kingdom.

For Casgevy specifically, SFDA registration status as of 2026 is evolving. Saudi families and their treating haematologist should confirm the current SFDA listing at intake. There are two practical paths, depending on registration status at the moment your case opens.

If Casgevy is on the SFDA registration list at the time of your case, standard prescription and import via the qualified Saudi treatment centre is the pathway. The dispensing hospital's pharmacy and the treating consultant coordinate the procurement and the administration.

If Casgevy is not yet registered in the kingdom at the time of your case, SFDA permits named-patient import of unregistered medicines on a physician-initiated basis where the drug is approved by a recognised reference authority (FDA, EMA, or MHRA), no clinically suitable locally registered alternative exists, and the treating consultant and dispensing hospital assume clinical responsibility. The application is filed via SFDA's drug.sfda.gov.sa portal by the dispensing hospital's licensed pharmacist on the consultant's behalf. Typical regulatory timing for a complete file on gene-therapy named-patient cases is four to eight weeks.

Either way, the regulatory layer is one of several layers that need to coordinate. The operational layer, the haematology and BMT workup, the family financial layer, and the timing of cell collection and Vertex manufacturing are the heavier ones.

Where Casgevy can be administered for a Saudi-based family

The historical centre of gravity for Saudi rare-disease and ATMP work is King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh. The KFSHRC bone marrow transplant programme is one of the oldest and deepest in the region. As of 2026, KFSHRC has the infrastructure and clinical depth to administer Casgevy, and the kingdom's haematology consultants typically refer rare-disease and ATMP cases through this network. KFSHRC Jeddah operates as the sister facility with the same research and clinical standards.

King Abdulaziz Medical City (KAMC) Riyadh, the National Guard Health Affairs flagship, has comprehensive paediatric haematology, rare-disease genetics, and the infrastructure for intensive peri-transplant management. KAMC is the alternative tertiary centre for ATMP cases in the kingdom.

For Saudi families whose case requires features that may not yet be available in-country, or who prefer treatment in the wider Vertex Authorized Treatment Center network, the established international options include Sidra Medicine in Doha (Qatar's qualified centre for paediatric SCD and TDT Casgevy administration), Yas Clinic Hospital in Abu Dhabi (which administered the UAE's first Casgevy case in April 2026 in partnership with Abu Dhabi Stem Cells Center and the Department of Health Abu Dhabi), and Vertex's US and European Authorized Treatment Center network.

For most Saudi-national families with KFSHRC or KAMC eligibility, the in-country path is the operationally simplest. For expatriate residents or families pursuing the case abroad for specific clinician relationships or for family logistics, cross-border coordination is straightforward.

The workup that decides eligibility

Several results need to land before the transplant pathway opens.

Confirmed diagnosis with detailed phenotype, documented VOC history (for SCD), transfusion history (for TDT), prior hydroxyurea response (for SCD), and iron-chelation history. Your haematologist's records typically cover this.

Bone marrow assessment including cytogenetics.

Cardiac function including echocardiogram and cardiac MRI for TDT patients with iron-overload concerns.

Pulmonary function.

Hepatic function including assessment of any prior hepatitis, iron overload, or transfusion-related hepatic effects.

Renal function.

Iron overload assessment for TDT patients, including T2-star cardiac MRI and liver iron quantification.

Infectious disease screening, CMV serology, and full immunisation review.

Fertility preservation counselling. Myeloablative conditioning typically causes permanent infertility. For adolescents, gamete preservation needs to be discussed before conditioning starts. This is a culturally sensitive conversation. We do not pretend it is anything other than serious. Your haematologist and the treatment centre's fertility-preservation team will lead it. We support the family with information and logistics.

Psychosocial assessment for the long inpatient stay and the recovery.

A clinical rationale letter from your treating haematologist documents the indication, severity, prior treatment history, and the proposed transplant plan.

The Saudi pathway in practice

For a Saudi family pursuing Casgevy at KFSHRC or KAMC, the practical sequence is referral from the treating haematologist, in-house transplant team assessment, SFDA documentation, mobilisation and apheresis, Vertex manufacturing wait of four to six months, conditioning, infusion, and recovery. The total arc from first call to infusion is typically close to a year.

For a Saudi family pursuing the case at Sidra Medicine in Doha or Yas Clinic in Abu Dhabi, the regulatory and logistical layer includes treatment-abroad funding documentation, family visa coordination for the long stay, and cross-border medical-record exchange. Reserve Meds coordinates the documentation and the family-side logistics. We are not the medical team. The transplant team and your haematologist run the clinical decisions.

The cost conversation, in the form a Saudi family needs

Casgevy's product list price in 2026 sits at approximately USD 2.2 million, or roughly SAR 8.25 million, for the cell-therapy product itself. That is the manufacturer's price. The full cost of care, including pre-treatment workup, mobilisation, apheresis, the four-to-six-month manufacturing waiting period, conditioning, the inpatient transplant admission, supportive care, and the first year of monitoring, adds substantially. Total cost of care for cross-border or cash-pay cases typically runs USD 2.8 to 3.5 million, or SAR 10.5 to 13.1 million.

For Saudi-national families being treated at KFSHRC or KAMC under public-sector frameworks, much of the cost may be underwritten through MoH structures or Vision 2030 pilot programmes. Your treating consultant and the hospital's patient navigator are the path to confirm what is currently available for your case. Reserve Meds will not speculate about the public-system financial structure on a public page.

For expatriate residents and self-pay families, the standard cash-pay-with-documentation pattern applies. We separate every line in the quote: cell-therapy product, mobilisation drugs, apheresis sessions, conditioning drugs, inpatient admission, supportive care, monitoring labs, our coordination fee. We do not put a markup on the manufacturer's drug price. Our coordination fee is disclosed in writing before any funds move.

CCHI listing and private-insurer coverage for one-time gene therapies remain limited. Bupa Arabia, Tawuniya, MedGulf, and Walaa handle these cases on a prior-authorisation basis; approval is uncommon outside Vision 2030 pilot frameworks. We provide the documentation packet that increases approval likelihood.

The year after

The first four to six weeks inpatient are the highest-acuity period. The patient is functionally immunocompromised during the engraftment window. Infection prophylaxis, transfusion support, and intensive monitoring run the daily care.

After discharge, the patient is on a structured outpatient follow-up: monthly haematology visits for the first year, with declining frequency thereafter. Transfusion requirement typically falls off within months for TDT patients who achieve engraftment, and VOC frequency typically falls off for SCD patients.

Long-term, lifelong haematology surveillance is standard. The vector is non-integrating from a genomic-insertion standpoint, but long-term monitoring is standard for any one-time gene therapy. Long-term data accumulation is ongoing globally.

Practical implications for a Saudi family: a substantial portion of a year of normal life is reorganised around the treatment. School attendance for adolescent patients will be interrupted for the inpatient and recovery period. We coordinate with the school on tutoring or remote-learning support as needed. Siblings, parents, and the extended family network typically reorganise schedules around the inpatient admission.

What Reserve Meds does for a Saudi family

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For a Saudi family pursuing Casgevy, our scope depends on where you choose to be treated.

For families being treated at KFSHRC or KAMC under MoH or Vision 2030 frameworks: we are most useful as a documentation and international second-opinion concierge layer. The in-country teams cover operational coordination. We can help with international second-opinion clinical reviews from Vertex Authorized Treatment Center transplant specialists, prior-authorisation documentation for private-insurance overlays, fertility-preservation logistics if you are routing internationally for that piece, and translation of medical records.

For families pursuing Sidra Medicine in Doha or Yas Clinic in Abu Dhabi: cross-border documentation and case coordination, family travel and accommodation for the lengthy stay, and continuity of care back to your treating haematologist in the kingdom.

For families pursuing international Casgevy (US or Europe Authorized Treatment Center): the standard Reserve Meds scope. SFDA documentation, qualified-centre liaison, named case-lead coordination from intake through one-year follow-up, travel and accommodation logistics, and the cross-border financial structure.

Reserve Meds is not your child's prescriber. We do not practise medicine. We do not manufacture Casgevy. We do not own or operate KFSHRC, KAMC, Sidra Medicine, Yas Clinic Hospital, or any other treatment centre. Clinical decisions stay with your treating haematologist and the transplant team.

We work cash-pay where applicable. Our coordination fee is disclosed in writing.

A note for families weighing this

Sickle cell disease and transfusion-dependent beta-thalassemia have deep roots in Saudi family histories. We assume you and your wider family have lived with this for years already, often across multiple affected family members. A potentially curative one-time therapy is a different kind of decision than the chronic-care adjustments you have made. We are not trying to push that decision. The right consultation pace is the one your treating haematologist and your family set together.

For Muslim families thinking through the religious-ethical dimension, the Islamic bioethics consensus on disease-modifying therapies that preserve life and function is broadly permissive, including for gene-editing therapies that do not alter the germline. The fertility-preservation conversation has its own religious-ethical layer; families typically consult both their treating clinician and their religious advisor before committing. We will not pressure either conversation.

Families typically take between two and six weeks from first call to readiness for the formal workup. The four-to-six-month manufacturing waiting period after cell collection means the total treatment arc is closer to a year. We are honest about that.

What to do if you want to start

If your child meets the basic eligibility (age 12 or older, SCD with recurrent VOCs or TDT), the first concrete step is a call with our case-lead so we can confirm the right pathway for your family. KFSHRC or KAMC in the kingdom, Sidra Medicine in Doha, Yas Clinic Hospital in Abu Dhabi, or an international Vertex Authorized Treatment Center.

If your child is under 12, has SCD without recurrent VOCs, or is in a situation where Casgevy is not currently the answer, reach out anyway. We can discuss timing, supportive care, and alternative options including Lyfgenia for eligible SCD patients.

Most families reach us first on WhatsApp, which we hold open during Saudi business hours and on weekends for active cases.

Start your child's case on the portal, or open a WhatsApp conversation with the case-lead and we will take it from there.

---

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating haematologist and the transplant team.

Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.